Interaction Effects in Clinical Trials

Ton J. Cleophas, Aeilko H. Zwinderman and Toine F. Cleophas
Additional contact information
Ton J. Cleophas: European Interuniversity College of Pharmaceutical Medicine Lyon
Aeilko H. Zwinderman: Academic Medical Center Amsterdam, Department Biostatistics and Epidemiology
Toine F. Cleophas: Technical University

Chapter Chapter 17 in Statistics Applied to Clinical Trials, 2006, pp 193-204 from Springer

Abstract: Abstract In pharmaceutical research and development, multiple factors like age, gender, comorbidity, concomitant medication, genetic and environmental factors co-determine the efficacy of the new treatment. In statistical terms we say they interact with the treatment efficacy. It is impossible to estimate all of these factors. Instead, randomized controlled trials are used to ensure that no major inbalances exist regarding these factors, and an overall assessment is made. The limitation of this approach becomes obvious once the new medicine is applied in practice where benefits of new medicines are far less consistent than they are in the trials.1 Despite this limitation, interaction effects, are not routinely assessed in clinical trials, probably because the statistical methods for identifying and integrating them into the data have low power. Moreover, if we introduce a large number of interaction terms in a regression analysis, the power to demonstrate a statistical significance for the primary endpoint will be reduced. Nonetheless, the assessment of a small number of interaction terms in clinical research can be an important part of the evaluation of new drugs, particularly, if it can be argued that the interaction terms make clinically sense. The current chapter gives some important factors that may interact with the treatment efficacy, and proposes some guidelines for implementing an interaction assessment in the analysis of clinical trials, in order to better predict the efficacy / safety of new medicines in future clinical treatment of individual patients.

Keywords: Calcium Antagonist; Treatment Efficacy; Lower Graph; Coronary Artery Diameter; Interaction Assessment (search for similar items in EconPapers)
Date: 2006
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-1-4020-4650-6_17

Ordering information: This item can be ordered from
http://www.springer.com/9781402046506

DOI: 10.1007/978-1-4020-4650-6_17

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().